Opportunities for CAR T-Cell Therapy in Solid Tumors

Video

Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.

"What is it about the solid tumor micro-environment that makes it challenging for T cells? One of the things is that it really is a tough environment for cells to survive in. The centers of solid tumors will become necrotic. They're very low-glucose, low-oxygen environments, a lot of down regulation of T cells. We came at things from that approach and said, 'Are there specific properties of a solid tumor micro-environment that we can arm the T cells to be able to survive better?'" —Geoffrey Hodge, chief executive officer of SOTIO BioTech US

Chimeric antigen receptor (CAR) T-cell therapy has proven to be efficacious for hematological indications, but its utility in solid tumors has been more of a challenge historically.

Many cell therapy developers are exploring combination therapies or secreting cytokines, but SOTIO is taking a different approach, according to Geoffrey Hodge, chief executive officer of SOTIO BioTech US.

"What is it about the solid tumor micro-environment that makes it challenging for T cells? One of the things is that it really is a tough environment for cells to survive in. The centers of solid tumors will become necrotic. They're very low-glucose, low-oxygen environments, a lot of down regulation of T cells," he told CGTL in an interview. "We came at things from that approach and said, 'Are there specific properties of a solid tumor micro-environment that we can arm the T cells to be able to survive better?'"

Hodge and Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, joined CGTL to discuss SOTIO, its 3 technology platforms, its pipeline of IL-15 Superagonists and antibody-drug conjugates, and the status of its clinical programs.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.